Table 1 Clinical trial combining epigenetic targetings with immunotherapies

DNMT inhibitors

Azacytidine

Nivolumab (anti-PD1)

AML, NSCLC, Osteosarcoma

NCT02397720 [136]; NCT03825367 [137]; NCT01928576 [138]; NCT03628209 [139]

Pembrolizumab (anti-PD1)

AML,CRC/microsatellite-stable CRC,HNSCC, Melanoma,MDS,NSCLC, PDAC,Ovarian primary peritoneal or fallopian tube cancer

NCT02546986 [140];

NCT02959437 [141];

NCT02845297 [142];

NCT03769532 [143]; NCT02260440 [144]; NCT02512172 [145]; NCT03094637 [146]; NCT02816021 [147]; NCT03264404 [148]; NCT02900560 [149]

Visilizumab(anti-PD1)

Relapsed Adult AML

NCT04722952 [150]

Atezolizumab (anti-PDL1)

MDS

NCT02508870 [151]

Avelumab (anti-PDL1)

AML

NCT02953561 [152]; NCT03390296 [153]

Durvalumab (anti-PDL1)

MDS, AML, NSCLC, Head and neck cancer, Breast cancer

NCT02775903 [154]; NCT02117219 [155]; NCT02250326 [156]; NCT03019003 [157]; NCT02811497 [158]

Ipilimumab (anti-CTLA4)

MDS

NCT02530463 [159]

Tremelimumab (anti-CTLA4)

MDS, Head and neck cancer

NCT02117219 [155]; NCT03019003 [157]

Pembrolizumab and epacadostat (IDO-1 inhibitor)

Advanced Solid Tumors, Non-Small Cell Lung Cancer, Microsatellite-Stable CRC

NCT02959437 [141]

Decitabine (DNMT1)

Camrelizumab (anti-PD1)

Hodgkin Lymphoma, PMBCL

NCT04514081 [160]; NCT03250962 [161]; NCT03346642 [162]

Nivolumab(anti-PD1)

Non-small Cell Lung Cancer

NCT02664181 [163]

Pembrolizumab (anti-PD1)

AML, MDS, CNS solid tumors, NSCLC, Breast cancer

NCT02996474 [164]; NCT03969446 [165]; NCT02957968 [166]; NCT03445858 [167]; NCT03233724 [168];

Avelumab (anti-PDL1)

AML

NCT03395873 [169]

pilimumab (anti-CTLA4)

MDS, AML

NCT02890329 [170]

Decitabine(with Chidamide, a HDAC inhibitor)

Camrelizumab (anti-PD1)

Hodgkin Lymphoma

NCT04514081 [160]

Guadecitabine(SGI-110)

Nivolumab (anti-PD1)

CRC

NCT03576963 [171]

Pembrolizumab (anti-PD1)

NSCLC, CRPC

NCT02998567 [172]; NCT02901899 [173]

Atezolizumab (Anti-PD-L1)

AML, MDS, urothelial carcinoma,Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma

NCT02892318 [174]; NCT02935361 [175]; NCT03179943 [176]; NCT03206047 [177]

Durvalumab (anti-PDL1)

Renal cancer, hepatocellular carcinoma, PDAC

NCT03308396 [178]; NCT03257761 [179]

Ipilimumab (anti-CTLA4)

Metastatic Melanoma

NCT02608437 [180]

Guadecitabine( with Mocetinostat HDAC inhibitor)

Pembrolizumab (anti-PD1)

NSCLC

NCT03220477 [181]

EZH2 inhibitors

Tazemetostat

Pembrolizumab (anti-PD1)

Urothelial carcinoma

NCT03854474 [182]

Atezolizumab (anti-PDL1)

DLBCL

NCT02220842 [183]

CPI-1205

Ipilimumab (anti-CTLA4)

Advanced solid tumours

NCT03525795 [184]

BET inhibitor

INCB057643

Pembrolizumab and epacadostat (IDO-1 inhibitor)

Advanced Solid Tumors, Non-Small Cell Lung Cancer, Microsatellite-Stable CRC

NCT02959437 [141]

BMS-986158

Nivolumab (anti-PD1)

haematologic malignancies

NCT02419417 [185]

LSD inhibitor

INCB059872

Pembrolizumab and epacadostat (IDO-1 inhibitor)

Advanced Solid Tumors, Non-Small Cell Lung Cancer, Microsatellite-Stable CRC

NCT02959437 [141]

Nivolumab (anti-PD1)

SCLC

NCT02712905 [186]

HDAC inhibitor

Chidamide with Decitabine

Immune checkpoint inhibitors(anti-PD1/PD-L1/CTLA4 antibodies)

Non-Hodgkin Lymphoma and advanced solid tumors

NCT05320640 [187]

Entinostat

Nivolumab (anti-PD1)

PDAC

NCT03250273 [188]

Pembrolizumab (anti-PD1)

Advanced solid tumours, Lymphomas, melanoma, bladder cancer, MDS

NCT03179930 [189]; NCT02936752 [190]; NCT03978624 [191]; NCT02437136 [192]; NCT02909452 [193]; NCT03765229 [194]

Nivolumab and ipilimumab

Renal cell carcinoma

NCT02453620 [195]; NCT03552380 [196]

Avelumab (anti-PDL1)

Ovarian cancer

NCT02915523 [197]

Mocetinostat

Nivolumab (anti-PD1)

NSCLC

NCT02954991 [198]

Pembrolizumab (anti-PD1)

NSCLC

NCT03220477 [181]

Durvalumab (anti-PDL1)

NSCLC

NCT02805660 [199]

Nivolumab and ipilimumab

Melanoma

NCT03565406 [200]

Vorinostat

Pembrolizumab (anti-PD1)

HNSCC, NSCLC, renal or urothelial cell carcinoma, Breast cancer, Glioblastoma, DLBCL, Hodgkin Lymphoma

NCT02638090 [201]; NCT03426891 [202]; NCT03150329 [203]; NCT02538510 [204]; NCT02619253 [205]; NCT02395627 [206]